VTYX Stock Risk & Deep Value Analysis
Ventyx Biosciences Inc
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on VTYX
We analyzed Ventyx Biosciences Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran VTYX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
📈VTYX Performance Overview3yr weekly
Unlock VTYX Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
VTYX Stock Risk Analysis
Overall Risk
Aggressive investment
Financial Risk
High
Market Risk
Medium
About Ventyx Biosciences Inc (VTYX)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
small
Market Cap
$504.86M
VTYX Deep Value Analysis
Compare VTYX to Similar Stocks
See how Ventyx Biosciences Inc stacks up against related companies in our head-to-head analysis.
VTYX Red Flags & Warning Signs
Premium- ⚠
Negative or inconclusive Phase 3 data for VTX958 in psoriasis
- ⚠
Regulatory hurdles or delays in approval process
- ⚠
Intensified competitive pressure from existing or emerging TYK2 inhibitors/other oral therapies
- ⚠
Failure to secure additional funding, leading to significant dilution
Unlock VTYX Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
VTYX Financial Health Metrics
Market Cap
$504.86M
VTYX Competitive Moat Analysis
PremiumMoat Rating
Narrow
Moat Trend
Expanding
Moat Sources
1 Identified
The moat is primarily derived from patent protection on VTX958 and its strong clinical profile. If VTX958 proves to be a best-in-class oral TYK2 inhibitor, its intellectual property will provide a durable, albeit time-limited, competitive advantage.
VTYX Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
VTYX Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated mid-May 2026)
- •Updates on VTX958 Phase 3 (SERENITY study) enrollment progress (ongoing)
- •Presentation of additional data for VTX958 in psoriatic arthritis or other indications at scientific conferences
Medium-Term (6-18 months)
- •Topline data readout from VTX958 Phase 3 psoriasis trial (expected H2 2026 - H1 2027)
- •Initiation of additional Phase 2/3 trials for VTX958 in other immunology indications (e.g., ulcerative colitis)
- •Potential strategic partnerships or licensing agreements for international markets
Long-Term (18+ months)
- •FDA submission and approval for VTX958 in psoriasis (late 2027 - 2028)
- •Commercial launch and market penetration of VTX958, aiming for best-in-class positioning
- •Pipeline expansion with other novel immunology assets
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
VTYX Bull Case: What Could Go Right
- ✓
Positive Phase 3 data for VTX958 demonstrating best-in-class efficacy/safety
- ✓
Acceleration in pipeline development and new indication initiations
- ✓
Strategic partnerships validating market potential
Bull Case Analysis
See what could go right with Premium
Never miss a move on VTYX
Create a free account to set price alerts and get notified on Telegram when VTYX hits your targets.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for Ventyx Biosciences Inc (VTYX)?
As of March 21, 2026, Ventyx Biosciences Inc has a DVR Score of 7.0 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Ventyx Biosciences Inc?
Ventyx Biosciences Inc's market capitalization is approximately $504.9M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Ventyx Biosciences Inc use?
VTYX is the ticker symbol for Ventyx Biosciences Inc. The company trades on the NMS.
What is the risk level for VTYX stock?
Our analysis rates Ventyx Biosciences Inc's overall risk as Aggressive investment. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the VTYX DVR analysis updated?
Our AI-powered analysis of Ventyx Biosciences Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 21, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.